Previous 10 | Next 10 |
Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Monday said it had exercised its option to acquire GeneTx Biotherapeutics for a $75M upfront payment following promising interim data from a phase 1/2 study of the privately-held biotech company's investigational drug GTX-102. ...
Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to higher doses Ultragenyx exercises option to acquire GeneTx for $75 million upfront payment Conference call to...
Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said it sold 30% of its royalty interest from Kyowa Kirin ( OTCPK:KYKOF ) on their drug Crysvita in the U.S. and Canada to Canadian public pension fund OMERS for $500M. OMERS' right to receive royalty ...
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the Ultragenyx royalty interest, subject to a 1.45x cap Proceeds to fund planned clinical and commercial activities NOVATO, Calif., July 14, ...
Ultragenyx is a rare disease drug developer. Its execution, so far, has been near perfect. The company has a long pipeline and oodles of cash. For further details see: Ultragenyx: Convincing Investment Thesis For This Orphan Drug Developer
Update 7:55am: Adds Times report on advisers for a potential deal. The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Friday after The Times reported that the Anglo-Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. In 201...
The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Monday after The Times reported that Anglo Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. AstraZeneca (AZN) already has a partnership with Mereo (MREO). According to the re...
Time to put money to work. Merger arb spreads are wide. Here’s what you can buy today. For further details see: Golden Age Of Merger Arb: Anaplan
NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....
NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...